USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: PSYCHOGENICS, INC.
City: TARRYTOWN
State: NY
Zip+4: 10591-
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $7,644,776.00 16
SBIR Phase II $2,284,490.00 2
STTR Phase I $577,800.00 1

Award List:

HIGHTHROUGHPUT ANALYSIS OF BEHAVIOR FOR CNS APPLICATIONS

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Daniela Brunner
Award Amount: $127,668.00
Abstract:
DESCRIPTION (provided by applicant): This application is submitted in response to the NIMH research topic, neuroscience and basic behavioral science in the SBIR solicitation. The goal of this project is to alleviate the bottleneck in psychiatric drug and target discovery and characterization of… More

DEVELOPMENT OF AMYGDALA SPECIFIC MONOCLONAL ANTIBODIES

Award Year / Program / Phase: 2002 / SBIR / Phase I
Agency: HHS
Principal Investigator: Andreas H. Kottmann
Award Amount: $123,906.00
Abstract:
DESCRIPTION (provided by applicant): In this application we propose to use "Differential Immunization for Antigen and Antibody Discovery" (DIAAD) technology, a novel differential immunization method established by Vacold L.L.C., and generate rat monoclonal antibodies to epitopes specific to the… More

Highthroughput analysis of behavior for CNS applications

Award Year / Program / Phase: 2003 / SBIR / Phase II
Agency: HHS
Principal Investigator: Daniela Brunner
Award Amount: $934,490.00

Wolframin gene ablation in mice as a model for human men

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Daniela Brunner
Award Amount: $448,546.00
Abstract:
DESCRIPTION (provided by applicant): We propose in this phase I SBIR application to generate and market a genetic model for a human psychiatric disorder(s) in mice by generating a loss of function mutation in the murine gene Wolframin 1 (mWfsl) through homologous recombination in ES cells. Both,… More

Spinal Cord Injury: Automatic Scoring of Motor Function

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Daniela Brunner
Award Amount: $234,554.00
Abstract:
DESCRIPTION (provided by applicant): Disorders of motor function due to accidental injury, stroke and neurodegenerative disorders, together with disorders of mental health, are the most crippling human ailments. One common result of mechanical insult is spinal cord injury (SCI), in which damage of… More

Animal Models of Schizophrenia: NRG-erbB Function

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Daniela Brunner
Award Amount: $500,000.00
Abstract:
DESCRIPTION (provided by applicant): This application is submitted in response to NIMH PA-02-027. The goal of this grant is to find a good model for schizophrenia based on gila dysfunction that can be used as a screening tool for antipsychotic drugs. An intense investigation of the role of glia in a… More

HIGH THROUGHPUT IN VIVO DRUG DISCOVERY-PHASE 1

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Emer Leahy
Award Amount: $500,000.00
Abstract:
DESCRIPTION (provided by applicant): The current trend in drug discovery is to develop drugs with a high level of selectivity for a single receptor. Although this is a real improvement for certain therapeutic areas, this may present a real issue for the development of novel treatments for… More

In Vivo Drug Discovery From Compound Mixtures

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: Emer Leahy
Award Amount: $468,176.00
Abstract:
DESCRIPTION (PROVIDED BY APPLICANT): Neuropsychiatric disorders are complex and involve multiple neuronal circuits. It is not surprising therefore that many of the most efficacious drugs in psychiatry have exceedingly complex pharmacology and were often discovered by observing how an animal's and… More

Higher Throughput Behavioral Screening of Cognitive

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: Daniela Brunner
Award Amount: $399,963.00
Abstract:
DESCRIPTION (provided by applicant): This application is submitted in response to NIMH research topic J1, neuroscience and basic behavioral science in the SBIR solicitation and PA-04-086, development of high throughput tools for brain and behavior. We aim to alleviate the bottleneck in drug… More

Nicotinic Ligands as Smoking Cessation Agents

Award Year / Program / Phase: 2007 / STTR / Phase I
Agency: HHS
Research Institution: UNVERSITY OF MISSISSIPPI MEDIC
Principal Investigator: Werner Tueckmantel
Award Amount: $577,800.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Tobacco use and nicotine addiction are an immense burden on the public health. There are an estimated 44.5 million (21%) adult smokers and an estimated 3.75 million (22%) high school student smokers in the US. Tobacco u se is responsible for over 440,000 deaths… More

Development of GSK-3 Beta Inhibitors for the Treatment of Parkinson's Disease

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jia Zhou
Award Amount: $564,868.00
Abstract:
DESCRIPTION (provided by applicant): Parkinson's disease (PD), a chronic and progressive neurological condition and one of aging and age- related diseases, affects approximately 1.5 million people in the US alone. PD not only places severe burden on the pa tients but also on their family and… More

High Throughput Behavioral Testing For Novel Antidepressants

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Barbara J. Caldarone
Award Amount: $500,000.00
Abstract:
DESCRIPTION (provided by applicant): CONFIDENTIAL Project Summary/Abstract This application is being submitted in response to an NIMH program announcement for Pharmacological Agents and Drugs for Mental Disorders. The goal of the proposal is to overcome th e major hurdles that have impeded the… More

Piperidine-Based Compounds as Therapeutics for Narcolepsy-Cataplexy

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jia Zhou
Award Amount: $500,000.00
Abstract:
DESCRIPTION (provided by applicant): Sleep deprivation and sleep disorders are estimated to cost Americans over 100 billion annually in lost productivity, medical expenses, sick leave, and property and environmental damage. Narcolepsy is a disabling illne ss and a key to understanding other sleep… More

Prodrugs of NAAG Peptidase Inhibitors for the Treatment of Schizophrenia

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jia Zhou
Award Amount: $620,426.00
Abstract:
DESCRIPTION (provided by applicant): Schizophrenia is a chronic, severe, and disabling brain disease. Nearly 1 percent of the population develops schizophrenia during their lifetime - more than 2 million Americans suffer from this disease in a given year. The schizophrenia world market generated… More

HDAC6-Selective Inhibitors for Pancreatic Cancer Treatment

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $366,682.00
Abstract:
DESCRIPTION (provided by applicant): Pancreatic cancer is the fifth leading cause of cancer death in the US. Despite tremendous efforts aimed at understanding its molecular biology, conventional treatment has had little impact. Due to the highly metastatic nature of the disease, surgery is… More

NAAG Peptidase Inhibitors for the Treatment of Traumatic Brain Injury

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: Jia Zhou
Award Amount: $760,811.00
Abstract:
DESCRIPTION (provided by applicant): Traumatic brain injury (TBI) is a serious public health concern. It is estimated that severe TBI will become the third most common cause of death and disability globally by the year 2020. An estimated 1.5 million person s sustain a TBI in the United States… More

High Throughput in Vivo Drug Discovery - Phase II

Award Year / Program / Phase: 2008 / SBIR / Phase II
Agency: HHS
Principal Investigator:
Award Amount: $1,350,000.00
Abstract:
DESCRIPTION (provided by applicant): This Phase II application is being submitted in response to a continuing NIMH program announcement for Pharmacological Agents and Drugs for Mental Disorders. The goal of the proposal is to use an innovative behavior-dri ven approach to psychiatric drug discovery… More

Eltoprazine for the Treatment of Cognitive Dysfunction Assoc. With Schizophrenia

Award Year / Program / Phase: 2011 / SBIR / Phase I
Agency: HHS
Principal Investigator: Emer Leahy – 914-593-0640
Award Amount: $700,000.00
Abstract:
DESCRIPTION (provided by applicant): Schizophrenia is a common and highly disabling psychiatric disorder with a population prevalence around 1%. The manifestations of schizophrenia fall into three major domains: 1) positive symptoms; 2) negative symptoms: and 3) cognitive dysfunction. All… More

Predictive Smoking Cessation Preclinical Battery

Award Year / Program / Phase: 2012 / SBIR / Phase I
Agency: HHS
Principal Investigator: Daniela Brunner – 914-406-8005
Award Amount: $829,176.00
Abstract:
DESCRIPTION (provided by applicant): Despite great advances in both the understanding of the neurobiology of addiction and the development and approval of smoking cessation therapies, a significant need remains for better smoking cessation aids. Our goal is aligned with NIDA's intent to bring… More